Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Brief summary (registry, in English)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

What you commit to

• Study type: Interventional · Phase 4
• Planned participants: 80
• From 3 Oct 2023 to the primary completion date, 22 Feb 2032
• 39 sites in 9 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (39)

Sites in registry order. Save your city in your profile to sort them by distance.